摘要
目的研究注射用头孢他啶阿维巴坦联用注射用硫酸多黏菌素B在肾移植患者中的安全性。方法分析1例29岁女性肾移植患者,予注射用硫酸多黏菌素B+注射用头孢他啶阿维巴坦联合抗感染治疗期间出现肌无力的病例,文献回顾硫酸多黏菌素B与头孢他啶阿维巴坦常见不良反应,分析不良反应发生原因。结果根据Karch和Lasagna评定法与Naranjo不良反应因果关系评估量表,考虑注射用头孢他啶阿维巴坦与注射用硫酸多黏菌素B联用致肌无力可能性大,调整抗感染方案为单用注射用头孢他啶阿维巴坦并调整给药剂量后,患者未再出现相关不良反应。结论联合使用注射用头孢他啶阿维巴坦和注射用硫酸多黏菌素B可能会增加肌无力不良反应发生风险。
Objective To study the safety of ceftazidime-avibactam for injection combined with polymyxins B Sulfate for injection in patients after renal transplantation.Methods The clinical data of a 29-year-old female patient with Klebsiella pneumonia infection after renal transplantation was analyzed,who had been treated with intravenous infusion of polymyxin B sulfate for injection and ceftazidime-avibactam,but her kidney preservation solution was sensitive to colistin and ceftazidime-avibactam.She presented with weakness of muscle during infusion of the sixth dose of ceftazidimeavibactam for injection.The possible causes of adverse reactions were analyzed.Results Based on the Karch and Lasagna method and Naranjo scale,both polymyxin B sulfate and ceftazidime-avibactam were discontinued.These symptoms did not recur after the patient received intravenous infusion of ceftazidime-avibactam alone.Conclusion The combination of ceftazidime-avibactam for injection and polymyxin B sulfate for injection may increase the risk of weakness of muscle.
作者
黄少兰
杨戈
李薇
HUANG Shaolan;YANG Ge;LI Wei(Department of Pharmacy,Hechuan People’s Hospital,Hechuan Chongqing 401520,China;Department of Pharmacy,Chongqing University Cancer Hospital,Chongqing 400030,China;Department of Pharmacy,the First Hospital Affiliated to Army Medical University,Chongqing 400038,China)
出处
《中国药物警戒》
2023年第5期583-584,590,共3页
Chinese Journal of Pharmacovigilance
基金
重庆市自然科学基金资助项目(cstc2020jcyjmsxmX0337)。
关键词
头孢他啶阿维巴坦
硫酸多黏菌素B
注射剂
肾移植
肌无力
感染
安全性
药品不良反应
ceftazidime-avibactam
polymyxin B sulfate
injection
kidney transplantation
weakness of muscle
infection
safety
adverse drug reaction
